David S Baldwin
Overview
Explore the profile of David S Baldwin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
237
Citations
3248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Huneke N, Cross C, Fagan H, Molteni L, Phillips N, Garner M, et al.
Int J Neuropsychopharmacol
. 2024 Apr;
27(4).
PMID: 38577951
Background: Anxiety disorders are highly prevalent and socio-economically costly. Novel pharmacological treatments for these disorders are needed because many patients do not respond to current agents or experience unwanted side...
12.
Reid J, Pellegrini L, Drummond L, Varlakova Y, Shahper S, Baldwin D, et al.
Int Clin Psychopharmacol
. 2024 Apr;
PMID: 38568112
Patients with obsessive compulsive disorder (OCD) randomised to sertraline, manualised cognitive behavioural therapy (CBT), or combination (sertraline + CBT), underwent cognitive assessment. Cognitive testing was conducted at baseline and at...
13.
Baldwin D, Adair M, Micheelsen A, Astrom D, Reines E
Curr Med Res Opin
. 2024 Jan;
40(3):483-491.
PMID: 38294154
Objective: Narrative review of the processes of goal setting and goal attainment scaling, as practical approaches to operationalizing and implementing the principles of shared decision making (SDM) in the routine...
14.
Domschke K, Seuling P, Schiele M, Bandelow B, Batelaan N, Bokma W, et al.
World Psychiatry
. 2024 Jan;
23(1):113-123.
PMID: 38214637
Anxiety disorders are very prevalent and often persistent mental disorders, with a considerable rate of treatment resistance which requires regulatory clinical trials of innovative therapeutic interventions. However, an explicit definition...
15.
Rai D, Webb D, Lewis A, Cotton L, Norris J, Alexander R, et al.
Trials
. 2024 Jan;
25(1):37.
PMID: 38212784
Background: Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed to manage anxiety in adults with an autism diagnosis. However, their effectiveness and adverse effect profile in the autistic population are...
16.
Baldwin D, Masdrakis V
Acta Neuropsychiatr
. 2023 Dec;
36(1):61-62.
PMID: 38124333
No abstract available.
17.
Huneke N, Amin J, Baldwin D, Chamberlain S, Correll C, Garner M, et al.
BMJ Open
. 2023 Nov;
13(11):e073946.
PMID: 38035741
Introduction: Given the high prevalence of mental health disorders and their significant socioeconomic burden, there is a need to develop improved treatments, and to evaluate them through placebo-controlled trials. However,...
18.
Bates A, Golding H, Rushbrook S, Shapiro E, Pattison N, Baldwin D, et al.
J Intensive Care Soc
. 2023 Sep;
24(3):309-319.
PMID: 37744073
Background: Approximately 50% of intensive care survivors experience persistent psychological symptoms. Eye-movement desensitisation and reprocessing (EMDR) is a widely recommended trauma-focussed psychological therapy, which has not been investigated systematically in...
19.
Masdrakis V, Konstantopoulou S, Baldwin D
Hum Psychopharmacol
. 2023 Jun;
38(4):e2879.
PMID: 37358233
No abstract available.
20.
Jauhar S, Arnone D, Baldwin D, Bloomfield M, Browning M, Cleare A, et al.
Mol Psychiatry
. 2023 Jun;
28(8):3149-3152.
PMID: 37322065
No abstract available.